An update on recombinant vaccines against leishmaniasis
Shital Shital1, Evanka Madan2, Angamuthu Selvapandiyan1
1Department of Molecular Medicine, Jamia Hamdard, India.
The Indian Journal of Medical Research
|December 5, 2024
Summary
Developing recombinant vaccines against Leishmania parasites is crucial for combating leishmaniasis (VL, CL, MCL). This review analyzes vaccine successes, challenges, and novel delivery systems for improved immunogenicity and disease eradication.
Area of Science:
- Parasitology
- Immunology
- Vaccine Development
Background:
- Leishmaniasis is a significant parasitic disease with visceral (VL), cutaneous (CL), and mucocutaneous (MCL) forms.
- Various vaccine candidates, including proteins, DNA, vectors, adjuvants, and recombinant whole parasites, have been explored against Leishmania species.
- Some Leishmania vaccine candidates have progressed to human clinical trials.
Purpose of the Study:
- To review all efforts in developing recombinant vaccines against Leishmania parasites.
- To analyze successes, including commercial canine vaccines, and identify challenges in vaccine development.
- To explore advancements in vaccine delivery systems for enhanced immunogenicity and targeted antigen delivery.
Main Methods:
- Comprehensive review of experimental and preclinical studies on Leishmania vaccine candidates.
- Analysis of data from human clinical trials of Leishmania vaccines.
- Examination of novel vaccine delivery systems, such as viral vectors and non-pathogenic bacteria.
Main Results:
- Several recombinant vaccine strategies have been developed and tested, with some showing promise and entering clinical trials.
- Commercially available canine vaccines demonstrate the feasibility of developing effective Leishmania vaccines.
- Advances in delivery systems like viral vectors and bacteria offer potential for improved vaccine efficacy.
Conclusions:
- Understanding past and current vaccine development efforts is key to refining future strategies.
- Novel delivery systems hold promise for enhancing immunogenicity and achieving long-lasting immune responses against Leishmania.
- Continued research and development are essential for the ultimate control and eradication of leishmaniasis.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...